欢迎来到latest obituaries from ely minnesota

latest obituaries from ely minnesota

【alan wake 2 tim breaker locations】ESTA Announces Participation in the Goldman Sachs Global Healthcare Conference

时间:2024-09-29 12:19:40 出处:Leisure阅读(143)

NEW YORK,alan wake 2 tim breaker locations June 03, 2020 (GLOBE NEWSWIRE) -- Establishment Labs Holdings Inc. (

ESTA

【alan wake 2 tim breaker locations】ESTA Announces Participation in the Goldman Sachs Global Healthcare Conference


), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced that CEO and Founder Juan José Chacón-Quirós and Chief Financial Officer Renee Gaeta will participate in the Goldman Sachs 41

【alan wake 2 tim breaker locations】ESTA Announces Participation in the Goldman Sachs Global Healthcare Conference


st

【alan wake 2 tim breaker locations】ESTA Announces Participation in the Goldman Sachs Global Healthcare Conference


Annual Global Healthcare Conference Webcast, which is being held June 9-11, 2020. Mr. Chacón-Quirós and Ms. Gaeta are scheduled to speak to conference attendees at 3:00pm ET on Wednesday, June 10, 2020.


A live webcast of the presentation will be available to all interested parties on the Establishment Labs investor relations website at


investors.establishmentlabs.com


. An archived version of the webcast will be available on the same website following the completion of the event.


About Establishment Labs


Establishment Labs Holdings Inc. (


ESTA


) is a global medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, by designing, developing, manufacturing and marketing an innovative portfolio of silicone gel-filled breast implants, branded as Motiva Implants®, the centerpiece of the MotivaImagine® platform. Motiva Implants® are produced at our two manufacturing sites that are compliant with ISO13485:2016, FDA 21 CFR 820 under the MDSAP program, and are currently commercially available in more than 80 countries through exclusive distributors or the Company’s direct salesforce. In March 2018, Establishment Labs received approval for an investigational device exemption (IDE) from the FDA and initiated the Motiva Implant® clinical trial in the United States in April 2018. In addition to Motiva Implants®, Establishment Labs’ product and technologies portfolio includes the Divina® 3D Simulation System and other products and services. Please visit our website for additional information at


www.establishmentlabs.com


.


Investor/Media Contact:


David K. Erickson


Establishment Labs Holdings Inc.


949-447-6671


[email protected]


View comments


分享到:

温馨提示:以上内容和图片整理于网络,仅供参考,希望对您有帮助!如有侵权行为请联系删除!

友情链接: